Category:
Other Excipients
CAS NO:
/
Standard:
In-house Standards,

For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. "Highlights: 1, Compared with tablets, hard capsule has higher bioavailability and is more rapid drug release. 2, Time to market: 2010 3, Exported countries: Belarus 4, Originator: BARACLUDE® by Bristol-Myers Squibb Co., launched in market in 2005 Registration Dossiers:non-clinical & clinical part, drug substance part and drug product part."